CONFERENCE ON THE COMPLICATIONS OF TREATMENT

促进对治疗并发症的研究的规划 对于儿童和青少年的癌症，我们建议举行为期三天的 关于这一主题的会议。第二国际的目标 儿童和青少年治疗的长期并发症会议 青少年抗癌组织将： A)对学员进行关于以下疾病的病理学和病理生理学的教育 辐射相关和蒽环类药物相关的心脏损伤； B)对学员进行培训，使他们了解目前的评价方法 心功能，包括心电图和超声心动图； C)对参与者进行有关心脏功能不全频率的教育 在儿童和青春期接受治疗的患者群体中 潜在的心脏毒性疗法； D)对参与者进行关于长期研究的其他现有研究的教育 儿童癌症幸存者；以及 E)通过以下方式促进与会者之间的互动 与会者建议的专题圆桌讨论 第一次会议。 会议将包括由全国和 辐射和辐射领域的国际公认的专家 与蒽环类药物相关的心脏病理、心脏的病理生理学 蒽环类药物相关性心肌病心功能的评价 远期存活者心功能的临床研究 儿童和青少年癌症。所有推荐的演讲者都有 同意参加这次会议。 会议将产生关于评价的建议， 心脏毒性暴露患者的临床处理与随访 治疗方法将通过出版 法律程序。

To facilitate planning for research into the complications of treatment of children and adolescents for cancer, we propose to hold a three-day conference on this topic. The goals of The Second International Conference on Long-Term Complications of Treatment of Children and Adolescents for Cancer will be to: A) Educate participants regarding the pathology and pathophysiology of radiation related and anthracycline related cardiac damage; B) Educate participants regarding current methods for evaluation of cardiac function, including electrocardiography and echocardiography; C) Educate participants regarding the frequency of cardiac dysfunction in populations of patients treated during childhood and adolescence with potentially cardiotoxic therapy; D) Educate participants regarding other current research on long-term survivors of childhood cancer; and E) Facilitate interaction among conference participants through roundtable discussions of topics suggested by the participants in the first conference. The conference will include presentations by nationally and internationally recognized experts in the areas of radiation and anthracycline related cardiac pathology, the pathophysiology of anthracycline related cardiomyopathy, the evaluation of cardiac function and clinical investigation of cardiac function in long-term survivors of pediatric and adolescent cancer. All of the suggested speakers have agreed to participate in the conference. The conference will lead to recommendations regarding evaluation, clinical management and follow-up of patients exposed to cardiotoxic therapies which will be disseminated through the publication of the Proceedings.